Cited by 372PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerProtein Kinase Regulation and GTPase Signaling

A possible linkage between AMP‐activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway

Kimura, Naoki, Tokunaga, Chiharu, Dalal, Sushila, Richardson, Christine, Yoshino, Ken‐ichi, Hara, Kenta, Kemp, Bruce E., Witters, Lee A. +2 more·2003·Genes to Cells

Abstract

Background: The mammalian target of rapamycin (mTOR) regulates multiple cellular functions including translation in response to nutrients, especially amino acids. AMP‐activated protein kinase (AMPK) modulates metabolism in response to energy demand by responding to changes in AMP. Results: The treatment of SV40‐immortalized human corneal epithelial cells (HCE‐T cells) with 5‐aminoimidazole‐4‐carboxamide ribonucleoside (AICAR), widely used as an AMPK activator, inhibits p70 S6k activities. Altered glucose availability, which regulates AMPK activity, also modulates the activity of p70 S6k. AICAR treatment also inhibits phosphorylation of Thr‐412 in the p70 S6 kinase (p70 S6k), which is indispensable for the activity. Furthermore, over‐expression of mutant AMPK subunits by stable expression in rabbit pulmonary fibroblast cell lines (PS120 cells) also modulates p70 S6k activity. The insensitivity of the rapamycin‐resistant p70 S6k variant to AICAR treatment suggests that the inhibition of p70 S6k is mediated through a common effector, supporting a model whereby mTOR and its downstream effector are controlled by AMPK. Conclusion: These results indicate that the AMPK and mTOR signalling pathways are possibly linked. In addition to the mTOR signal acting as a priming switch that modulates p70 S6k activation, AMPK appears to provide an overriding switch linking p70 S6k regulation to cellular energy metabolism.

Integrity signals

Registry

Crossref · 10.1046/j.1365-2443.2003.00615.x

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treatment with AICAR inhibits S6K (mTOR effector) activity in a range of mammalian cells.

    “For example treatment with AICAR inhibits S6K (mTOR effector) activity in a range of mammalian cells [150].”

    From AMPK and Exercise: Glucose Uptake and Insulin Sensitivity (2013) · cites this paper as [150]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kimura, N., Tokunaga, C., Dalal, S., Richardson, C., Yoshino, K., Hara, K., Kemp, B. E., Witters, L. A., Mimura, O., & Yonezawa, K.
Affiliations
  • Hyogo Medical University (JP)
  • Biosignal Research Center, Kobe University (JP)
  • Dartmouth College (US)
  • St Vincents Institute of Medical Research (AU)
Corresponding author
Yonezawa, Kazuyoshi
Venue
Genes to Cells
Publisher
Wiley
Published
2003-01
Volume
8
Issue
1
Pages
65-79
ISSN
  • 1356-9597 (ISSN-L)
  • 1365-2443
OpenAlex
W1993363796
Cited by
372
References
52
Citations by year
2026: 2 · 2025: 6 · 2024: 7 · 2023: 13 · 2022: 9 · 2021: 11 · 2020: 13 · 2019: 17 · 2018: 7 · 2017: 16 · 2016: 23 · 2015: 21 · 2014: 9 · 2013: 28 · 2012: 13
FWCI
9.19
Type
journal article
Language
en
Open access
closed
Locations
  • Genes to Cells (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (DK-35712, R01DK035712)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
AMPK, mTOR signaling, p70 S6 kinase, AICAR, AMPK activation, glucose availability, energy metabolism, rapamycin resistance, corneal epithelial cells, lung fibroblasts, amino acid signalling, translational regulation
MeSH terms
Aminoimidazole Carboxamide, Drug Interactions, Humans, Hypoglycemic Agents, Insulin, Multienzyme Complexes, Phosphorylation, Protein Kinases, Proto-Oncogene Proteins, Ribonucleotides, Tumor Cells, Cultured, Signal Transduction, Protein Serine-Threonine Kinases, Ribosomal Protein S6 Kinases, 70-kDa, Proto-Oncogene Proteins c-akt, AMP-Activated Protein Kinases, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review